The Pharma Data

JUNE 19, 2023

The findings bolster the idea, which is currently under investigation in at least three clinical trials, that when it comes to treating resistant breast cancer, two drugs may be better than one.

Drugs 40

Drugs HR Scientist Hormones 40

XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

The Pharma Data

FEBRUARY 21, 2022

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. billion euros.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

APRIL 28, 2022

The new hub will focus on centralising things like clinical development strategy, clinical operations, and regulatory approval strategy – not necessarily drug development itself. When a company, a big pharma company, calculates the financial impact, they also consider the sales force that they need, the marketing.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

OCTOBER 26, 2020

Sales. As monotherapy for the treatment of BRCA 1/2 metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed following a prior therapy that included a new hormonal agent based on the Phase 3 PROfound trial. Total Sales. Total Sales.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program. The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. billion euros.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation.

HR 52

HR Medicine Hormones Trials 52

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

JANUARY 10, 2021

By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?. . . . . ?.

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246